Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood-brain barrier transport of oxycodone

Drug Metabolism and Disposition

Volumn 36, Issue 10, 2008, Pages 2005-2013

  Okura, Takashi ^a   Hattori, Asami ^a   Takano, Yusuke ^a   Sato, Takenori ^a   Hammarlund Udenaes, Margareta ^b   Terasaki, Tetsuya ^c   Deguchi, Yoshiharu ^a  

^a TEIKYO UNIVERSITY   (Japan)

^b UPPSALA UNIVERSITY   (Sweden)

^c TOHOKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; AMANTADINE; AMMONIUM CHLORIDE; CARBONYL CYANIDE 4 (TRIFLUOROMETHOXY)PHENYLHYDRAZONE; CARNITINE; CATION; CORTICOSTERONE; MEPYRAMINE; ORGANIC CATION TRANSPORTER; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; OXYCODONE; PROTON; PYRILAMINE TRANSPORTER; QUINIDINE; ROTENONE; SODIUM; SODIUM AZIDE; TETRYLAMMONIUM; THIONEINE; TRITIUM; UNCLASSIFIED DRUG; VERAPAMIL;

ACIDIFICATION; ALKALINITY; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN PERFUSION; CAPILLARY ENDOTHELIUM; CELL LINE; CONCENTRATION RESPONSE; DRUG TRANSPORT; ENDOTHELIUM CELL; MEMBRANE POTENTIAL; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; RAT; TEMPERATURE DEPENDENCE;

ANIMALS; BLOOD-BRAIN BARRIER; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CARRIERS; GENE EXPRESSION PROFILING; HISTAMINE H1 ANTAGONISTS; MALE; ORGANIC CATION TRANSPORT PROTEINS; OXYCODONE; POLYMERASE CHAIN REACTION; PYRILAMINE; RATS; RATS, WISTAR; TRITIUM;

RATTUS;

EID: 52949145587     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.022087     Document Type: Article

References (31)

1. Allen DD and Smith QR (2001) Characterization of the blood-brain barrier choline transporter using the in situ rat brain perfusion technique. J Neurochem 76:1032-1041.
2. Boström E, Simonsson US, and Hammarlund-Udenaes M (2005) Oxycodone pharmacokinetics and pharmacodynamics in the rat in the presence of the P-glycoprotein inhibitor PSC833. J Pharm Sci 94:1060-1066.
3. Boström E, Simonsson US, and Hammarlund-Udenaes M (2006) In vivo blood-brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharma-cokinetics/pharmacodynamics. Drug Metab Dispos 34:1624-1631.
4. 1-specific opioid peptide, H-Tyr-D-Arg-Phe-β-Ala-OH (TAPA). J Neurochem 84:1154-1161.
5. Deguchi Y, Yokoyama Y, Sakamoto T, Hayashi H, Naito T, Yamada S, and Kimura R (2000) Brain distribution of 6-mercaptopurine is regulated by the efflux transport system in the blood-brain barrier. Life Sci 66:649-662.
6. Gomes P and Soares-da-Silva P (1999) Interaction between l-DOPA and 3-O-methyl-L-DOPA for transport in immortalised rat capillary cerebral endothelial cells. Neuropharmacology 38:1371-1380.
7. Hosoya KI, Takashima T, Tetsuka K, Nagura T, Ohtsuki S, Takanaga H, Ueda M, Yanai N, Obinata M, and Terasaki T (2000) mRNA expression and transport characterization of conditionally immortalized rat brain capillary endothelial cell lines; a new in vitro BBB model for drug targeting. J Drug Target 8:357-370.
8. Inui KI, Masuda S, and Saito H (2000) Cellular and molecular aspects of drug transport in the kidney. Kidney Int 58:944-958.
9. Kageyama T, Nakamura M, Matsuo A, Yamasaki Y, Takakura Y, Hashida M, Kanai Y, Naito M, Tsuruo T, Minato N, et al. (2000) The 4F2hc/LAT1 complex transports l-DOPA across the blood-brain barrier. Brain Res 879:115-121.
10. Kido Y, Tamai I, Ohnari A, Sai Y, Kagami T, Nezu J, Nikaido H, Hashimoto N, Asano M, and Tsuji A (2001) Functional relevance of carnitine transporter OCTN2 to brain distribution of L-carnitine and acetyl-L-carnitine across the blood-brain barrier. J Neurochem 79:959-969.
11. Koepsell H, Schmitt BM, and Gorboulev V (2003) Organic cation transporters. Rev Physiol Biochem Pharmacol 150:36-90.
12. Kokubun H, Ouki M, Matoba M, Kubo H, Hoka S, and Yago K (2005) Determination of oxycodone and hydrocotarnine in cancer patient serum by high-performance liquid chromatography with electrochemical detection. Anal Sci 21:337-339.
13. Kusuhara H, He Z, Nagata Y, Nozaki Y, Ito T, Masuda H, Meier PJ, Abe T, and Sugiyama Y (2003) Expression and functional involvement of organic anion transporting polypeptide subtype 3 (Slc21a7) in rat choroid plexus. Pharm Res 20:720-727.
14. Mori S, Takanaga H, Ohtsuki S, Deguchi T, Kang YS, Hosoya K, and Terasaki T (2003) Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells. J Cereb Blood Flow Metab 23:432-440.
15. Mori S, Ohtsuki S, Takanaga H, Kikkawa T, Kang YS, and Terasaki T (2004) Organic anion transporter 3 is involved in the brain-to-blood efflux transport of thiopurine nucleobase analogs. J Neurochem 90:931-941.
16. Nezu J, Tamai I, Oku A, Ohashi R, Yabuuchi H, Hashimoto N, Nikaido H, Sai Y, Koizumi A, Shoji Y, et al. (1999) Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nat Genet 21:91-94.
17. + antiporter in the kidney. Drug Metab Dispos 34:1868-1874.
18. Ohtsuki S, Asaba H, Takanaga H, Deguchi T, Hosoya K, Otagiri M, and Terasaki T (2002) Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain. J Neurochem 83:57-66.
19. Okura T, Ito R, Ishiguro N, Tamai I, and Deguchi Y (2007) Blood-brain barrier transport of pramipexole, a dopamine D2 agonist. Life Sci 80:1564-1571.
20. Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, and Moriyama Y (2005) A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci USA 50:17923-17928.
21. Pardridge WM (2005) The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2:3-14.
22. Sipos H, Törocsik B, Tretter L, and Adam-Vizi V (2005) Impaired regulation of pH homeostasis by oxidative stress in rat brain capillary endothelial cells. Cell Mol Neurobiol 25:141-151.
23. Takasato Y, Rapoport SI, and Smith QR (1984) An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am J Physiol 247:H484-H493.
24. Taylor CJ, Nicola PA, Wang S, Barrand MA, and Hladky SB (2006) Transporters involved in regulation of intracellular pH in primary cultured rat brain endothelial cells. J Physiol 576:769-785.
25. +/organic cation antiporter MATE1. Pharm Res 23:1696-1701.
26. Terasaki T, Ohtsuki S, Hori S, Takanaga H, Nakashima E, and Hosoya K (2003) New approaches to in vitro models of blood-brain barrier drug transport. Drug Discov Today 8:944-954.
27. Tsuji A (2005) Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems. NeuroRx 2:54-62.
28. Tunblad K, Jonsson EN, and Hammarlund-Udenaes M (2003) Morphine blood-brain barrier transport is influenced by probenecid co-administration. Pharm Res 20:618-623.
29. Yamazaki M, Fukuoka H, Nagata O, Kato H, Ito Y, Terasaki T, and Tsuji A (1994a) Transport mechanism of an H1-antagonist at the blood-brain barrier: transport mechanism of mepyra-mine using the carotid injection technique. Biol Pharm Bull 17:676-679.
30. Yamazaki M, Terasaki T, Yoshioka K, Nagata O, Kato H, Ito Y, and Tsuji A (1994b) Carrier-mediated transport of H1-antagonist at the blood-brain barrier: mepyramine uptake into bovine brain capillary endothelial cells in primary monolayer cultures. Pharm Res 11:975-978.
31. Yamazaki M, Terasaki T, Yoshioka K, Nagata O, Kato H, Ito Y, and Tsuji A (1994c) Carrier-mediated transport of H1-antagonist at the blood-brain barrier: a common transport system of H1-antagonists and lipophilic basic drugs. Pharm Res 11:1516-1518.